Volver a la clasificación

Reckitt Benckiser Group plc (RBGPF)

Sobrevalorada
Consumer DefensiveHousehold & Personal ProductsUnited Kingdom

Fundamental

53

Precio

$4907.00

Capitalización Bursátil

$31.22B

Parte 1 · Cuánto vale la empresa

Resumen

Reckitt Benckiser makes and sells branded household health and hygiene products: disinfectants and cleaners such as Lysol and Dettol, over-the-counter medicines such as Nurofen and Strepsils, condoms under Durex, and infant formula through its Mead Johnson Nutrition unit. It manufactures its own products and sells them through supermarkets, pharmacies and e-commerce worldwide. On 31 December 2025 it completed the sale of its Essential Home division (Air Wick, Calgon, Cillit Bang and about 75 other brands) to Advent International, keeping a 30% stake in the buyer.

Cómo genera ingresos

Revenue comes from selling packaged consumer goods through retailers, who buy at wholesale prices and mark them up for shelf sale. Margins depend on brand strength: a well-known name lets Reckitt charge more than an unbranded or store-label equivalent for a nearly identical product. Since January 2025 the group reports by geography — Core Emerging Markets, Core Europe, Core North America — plus Mead Johnson Nutrition as a separate line, after moving away from its former Health/Hygiene/Nutrition split.

Ventaja competitiva

Marca · Estrecha

Reckitt owns a portfolio of category-leading brands built over decades — Dettol in disinfection, Durex in condoms, Nurofen in pain relief — that let it command a premium over unbranded rivals. The advantage is narrow rather than wide: retailers' own store brands and generic pharmacy equivalents compete directly on price in most of these categories, and brand loyalty alone does not stop customers from trading down when budgets tighten.

Qué impulsa la demanda

Defensivo

Most of the portfolio — disinfectants, pain relief, feminine care — covers routine household purchases that people keep buying even in a downturn, which cushions the group against recessions. The exception is infant nutrition, where demand tracks birth rates rather than the economy: Mead Johnson's growth in 2025 came mainly from price and mix rather than more babies being fed, since volumes actually declined.

Los argumentos a favor

Buyers argue that the 2025 turnaround is real — Core Reckitt like-for-like revenue grew 5.2%, led by double-digit growth in Emerging Markets — and that the Essential Home sale sharpens the portfolio around higher-margin health and hygiene brands while returning capital to shareholders through a special dividend.

Los argumentos en contra

Sellers point to a stalled Europe (like-for-like revenue down 4.5% in 2025) and soft North America, and worry that hundreds of pending U.S. lawsuits alleging Enfamil premature-infant formula causes necrotizing enterocolitis — with a jury already awarding $60 million in one case — could impose costs and reputational damage far beyond what today's price assumes.

Written by the editors, published on 18 de agosto de 2026

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance y Liquidez

Ingresos

$13.34B

Últimos 12 meses hasta el último trimestre publicado — estimación a partir de métricas por acción

Beneficio Neto

$2.81B

Últimos 12 meses hasta el último trimestre publicado — estimación a partir de métricas por acción

Flujo de Caja Libre

$3.09B

Patrimonio Neto Total

$5.66B

Pasivo Total

$10.25B

Ratio de Liquidez

0.59

Cobertura de Intereses

-

Deuda/EBITDA

2.86

Beneficio Por Acción

Ingresos y Beneficio Neto

Flujo de Caja Libre

Desglose de Ingresos

Estado histórico

Márgenes en el tiempo

La deuda en el tiempo

Cuánto pesa la deuda

Cuadro de crecimiento

Crecimiento — Ingresos

Estimación de Valor Justo

Caso generalSobrevalorado

Valor Justo

$2161.88

Precio Actual

$4907.00

Margen de Seguridad

-127.0%

Rango de Valor Justo

$1405.23 - $2918.54

Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.

Métodos de Estimación

Precio objetivo de los analistas:$6239.05
Flujo de caja descontado (DCF):$178.69
Múltiplo sobre beneficios (P/E):$62.47
Fórmula de crecimiento de Graham:$220.37
Valor de la capacidad de generar beneficios (EPV):$42.55
P/B justificado:$65.46
Descuento de dividendos (Gordon):$31.39
P/FFO, fondos de operaciones:Datos insuficientes para calcularlo
Beneficios de mitad de ciclo:Datos insuficientes para calcularlo
Múltiplo sobre ingresos:$24.92
Consenso de Analistas:Compra Fuerte (22B / 7H / 0S)
Última Sorpresa de Resultados:-1.27%

Métricas de Valoración

Ratio P/E

1127.52

ROE

48.0%

Ratio P/B

559.11

P/FCF

1008.96

Margen Bruto

59.6%

ROIC

12.3%

Radar de Rentabilidad

Creación de Valor (Ventaja Competitiva)

ROIC

12.3%

WACC

8.4%

ROIC − WACC

+3.9 pp

El ROIC supera el coste del capital: la empresa está creando valor para los accionistas.

Criterios de Análisis Fundamental

Superado (10)

  • ROIC 12.3%
  • Gross Margin 59.6%
  • Debt/Equity ratio
  • Operating Margin 28.5%
  • Positive Free Cash Flow
  • Debt/EBITDA
  • ROE 42.9%
  • Analyst Consensus 76% Buy
  • PEG Ratio 0.46
  • Net Margin Trend 22.4% vs 10.1%

Fallido (11)

  • Price CAGR -3.61%
  • P/FCF 1008.96
  • P/B Ratio 559.11
  • CapEx intensity
  • Current Ratio
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Revenue Growth 5Y 0.3%
  • Earnings Surprise avg 2.4%
  • Earnings Quality (OCF/NI) 0.66
  • Piotroski F-Score 1/9

No disponible (6)

  • EPS data insufficient
  • Dividend Payout NaN%
  • Interest Coverage
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Share Dilution (missing shares data)

Piotroski F-Score

1/9

Preocupaciones financieras graves

score
criteria

Calidad de los Beneficios

0.66

Moderada: cierta brecha entre beneficios y efectivo

Dilución de Acciones

-

Recomprando acciones. Favorable para el accionista

Participaciones institucionales

No hay declaraciones institucionales para esta empresa.

Gobernanza

Equipo Directivo

NombreCargoEdad
Mr. Kristoffer Loe LichtCEO & Executive Director49
Ms. Shannon Sue EisenhardtCFO & Executive Director51
Mr. Nicholas James Ashworth C.F.A.Senior Vice President of Investor Relations-
Ms. Catheryn O'RourkeSenior VP, General Counsel & Company Secretary52
Ms. Sheila RedzepiChief Communications & Corporate Affairs Officer46
Mr. Ranjay RadhakrishnanChief Human Resources Officer54
Mr. Jerome LemairePresident North America51
Ms. Angela Naef Ph.D.Chief Research & Development Officer49
Ms. Susan SholtisPresident of Nutrition58
Dr. Alessio Fasano M.D.Chief Science & Medical Officer of Mead Johnson Nutrition (MJN) Business-

Riesgo de Auditoría

4

Riesgo del Consejo

5

Riesgo de Compensación

3

Riesgo de Derechos del Accionista

1

Parte 2 · El precio y el momento de entrar

Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.

Latest News

Recent headlines for RBGPF, sourced from Markets Gazette.

No recent news for RBGPF.